Skip to main content
. Author manuscript; available in PMC: 2014 Sep 1.
Published in final edited form as: Autoimmunity. 2010 Mar;43(2):140–155. doi: 10.3109/08916930903229239

Figure 7.

Figure 7

GpG-ODN suppresses both in vivo IL-12(p40) production and in vitro proliferative responses to a TLR-7 agonist. (A) Female 12-week old NZB/W mice (3 per group) were treated with PBS, CpG-ODN, or GpG-ODN on day 0 (grey arrow). At the times indicated (black arrows), splenocytes were harvested and stimulated in vitro with CpG-ODN or GpG-ODN at 5 µg/ml, or 1 mM loxoribine for 24h. (B) Sera were collected at the indicated times, and levels of IL-12(p40) were assayed by ELISA. Proliferation of cells harvested 3 days (C) or 7 days (D) after initial treatment was assessed by thymidine incorporation assay. *Data from experiments performed at 1 and 2 days did not indicate any statistically significant differences, and thus are not shown. Results are expressed as a stimulation index. Bars represent mean + SD. For panel (B), symbols represent statistically significant differences (p < 0.05) as follows: +CpG versus PBS; *GpG versus PBS; #GpG versus CpG. For panels (C) and (D), symbols above the bars indicate significant inhibition of splenocyte proliferation in response to in vitro loxoribine stimulation: +CpG versus PBS; *GpG versus PBS; #GpG versus CpG.